
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNeTdSS2NDTVhLUE5TdFA0OHNxd29QckI2N0s1d3ZpRDF3dHRSWE52dEZDa2RfbzBCUXZwakViWmVITDhZTVlFOWFvRVZTQXA3c0o3TXhBVzRpN2lMRG9kVW5KVzNKQktyZ21xUjVod3dTTkk2dVZIM2dIblFlN3N2Tm1LVWtxLWcwd05lT196cDBUNWNUcWxFbW40U2w4QkhqNDdyR1BGSzRPaUc3Rk9QMEM3X0R1NVpFeGc?oc=5" target="_blank">Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis</a>&nbsp;&nbsp;<font color="#6f6f6f">Yahoo Finance</font>